IP Verse

Soluble Estradiol Capsule For Vaginal Insertion - EP2861073

The patent EP2861073 was granted to Therapeuticsmd on Apr 14, 2021. The application was originally filed on Jun 18, 2013 under application number EP13807188A. The patent is currently recorded with a legal status of "Revoked".

EP2861073

THERAPEUTICSMD
Application Number
EP13807188A
Filing Date
Jun 18, 2013
Status
Revoked
Sep 23, 2022
Publication Date
Apr 14, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

RIECKJan 14, 2022FUCHS PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS6018033
DESCRIPTIONUS6060077
INTERNATIONAL-SEARCH-REPORTUS2005042268
INTERNATIONAL-SEARCH-REPORTUS2006134188
INTERNATIONAL-SEARCH-REPORTUS2007264349
INTERNATIONAL-SEARCH-REPORTUS2007287789
INTERNATIONAL-SEARCH-REPORTUS4384096
INTERNATIONAL-SEARCH-REPORTUS6294192
OPPOSITIONUS6060077
OPPOSITIONWO2013078422
OPPOSITIONWO9740823
SEARCHUS6060077
SEARCHWO2007076144
SEARCHWO2013078422
SEARCHWO2013192251

Non-Patent Literature (NPL) Citations (13) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- CINDY H. DUBIN, "Transdermal, Topical & Subcutaneous: Non-Invasive Delivery to Expand Product Line Extensions", Drug Development & De- livery, (20120000), vol. 12, no. 6, pages 51 - 57, XP055892882
OPPOSITION- CODONI, "Development and physical characterisation of polyethylene glycol glycerides- based gel formulations for macromolecule delivery", PhD thesis at University of East Anglia, (20131200), XP055892529
OPPOSITION- DAVID J. HAUSS, "Materials, Process, and Manufacturing Considerations for Lipid-Based Hurd-Capsule Formats", Oral Lipid-Based Formulations - Enhancing the Bioa- vailability of Poorly Water -Soluble Drugs, (20070000), XP055892862
OPPOSITION- "Gelucire® 50/13", GATTEFOSSE, (2019), URL: https://www.gattefosse.com/pharmaceuticals-products/gel uci re-50 13, XP055892543
OPPOSITION- JANET A CHOLLET, "Efficacy and safety of ultra-low-dose Vagifem (10 µg", Patient Preference and Adherence, (20110000), vol. 5, pages 571 - 574, XP055892841
OPPOSITION- KUMAR et al., "Paliperidone loaded spherical solid lipid nanoparticles", RSC Advances, (20120000), XP055892536
OPPOSITION- PODCZECK et al., "chapter 9 filling of liquids and semi-solids into hard two-piece capsules", Pharmaceutical Capsules, (20040000), pages 169 - 173, XP055892876
OPPOSITION- "Polygynax®", HAS Commission de la Transparence, (20180110), pages 1 - 18, XP055892884
OPPOSITION- "Resume des caracteristiques de produit Utrogestan capsules molles", Utrogestan®, (201602), XP055892852
OPPOSITION- "RESUME DES CARACTERISTIQUES DU PRODUIT UTROGESTAN VAGINAL capsules molies", Utrogestan, (201602), XP055892857
OPPOSITION- "Vagifem 10 micrograms vaginal tablets", Novo Nordisk Limited, (20201207), pages 1 - 8, XP055892846
OPPOSITION- "Vagifem 25mcg to be discontinued", MPR THE RIGHT DOSE OF INFORMATION, (20100520), XP055892847
OPPOSITION- Laura M. Land, et al, "The Influence of Water Content of Triglyceride Oils on the Solubility of Steroids", Pharmaceutical Research, (20050000), pages 784 - 788, XP019370851

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents